StemCell Therapy

MIRAMAR, Fla., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation(www.generex.com) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020 at 11:00AM Eastern time.

Agenda

On the call, Mr. Moscato and his team will provide an overview of how NuGenerex Immuno-Oncologys Ii-Key technology is clinically proven to activate the immune system against numerous viruses including H5N1 avian influenza virus and a review of work with development partners & government agencies to implement Ii-Key peptide vaccines to implement a rapid response vaccination strategy that can provide immunity to the 2019-nCOV and Avian influenza (Bird Flu). Additionally, management will discuss the opportunity for NuGenerex Diagnostics to develop a rapid test for 2019-nCOV in respiratory and blood samples using its proprietary NGDx Express 2 rapid diagnostic technology.

Mr. Moscato will also provide details on a variety of upcoming corporate actions, including closing of the ALTuCELL acquisition, the S1 funding, an update on the Nasdaq listing process, the public spinout of NGIO directly to Nasdaq, and an overview of plans to initiate the Arizona operations and partnerships with physician groups to establish an end-to-end, comprehensive solution for managing patients with diabetes.

Mr. Moscato said, As announced last week, we will finally pay our stock dividend to our valuable shareholders on February 24th. This dividend fulfills the promises we made when we took over as management three years ago to reward shareholders when we advance our strategy to rebuild Generex. Once the dividend is paid, we can price the S1 and take in our funding, which will enable us to execute on our go forward plans. The S1 funding will allow us to close ALTuCELL and initiate clinical trials of their cell encapsulation technology for the treatment of Type I and Type II diabetes. Continuing our efforts in diabetes management, we plan to start our Arizona operations and begin the buildout of our multi-specialty, integrated care model for diabetes patients in collaboration with our physician partners at three major primary care and endocrinology practices under the banner of NuGenerex Health. Additionally, we have secured a surgery center as part of our integrated care model, which will advance our ultimate goal to set up the NuGenerex Health MSO and HMO in Arizona.

Mr. Moscato continued, With the impending S1 funding, we can fully fund the commercial operations of our subsidiaries with the sales, marketing, and operating budgets that our FDA cleared products deserve. We will expand the Excellagen sales force, and roll out two new product offerings from Olaregen, Dermacell and Olarex, which we expect to generate significant sales going forward. We are also excited about the launch of Excellagen Aesthetics in the aesthetic dermatology market. We will also expand the sales and marketing effort and build the inventory of MediSource Partners and Pantheon to focus on geographic expansion and revenue growth.

In addition to funding our revenue generating subsidiaries we will fund our clinical development stage subsidiaries, including Regentys, which will initiate the manufacturing and clinical supply of Extra-Cellular Matrix Hydrogel (ECMH) for the treatment of ulcerative colitis and inflammatory bowel diseases. We will continue to fund NuGenerex Immuno-Oncology and our ongoing Phase II clinical trial of AE37 peptide immunotherapeutic vaccine in combination with pembrolizumab (Mercks Keytruda) which is currently recruiting patients. We are excited that once the dividend is paid, we will be able to execute on all of our endeavors that will manifest into the enterprise we envisioned when we took over Generex with a promise to build shareholder value. Part of that strategy was to reclaim the value of our immunotherapy assets that include AE37 and the Ii-Key technology for cancer immunotherapy, and we are now positioned to realize that goal through the spin-out of NuGenerex immuno-Oncology (NGIO) as a separate public company on the Nasdaq.

Mr. Moscato concluded, The emergence of the coronavirus pandemic reminds us of the mid-2000s when Generex maintained a robust and successful research effort to make a rapid-response pandemic virus vaccine based on the Ii-Key technology that the company utilizes for our cancer immunotherapy program. A decade ago, Dr. Eric von Hofe, Chief Scientific Officer of NGIO and his team developed potential Ii-Key peptide vaccines for avian influenza (bird flu), swine flu, and SARS. Dr. von Hofe will discuss how Generex can revive the Ii-Key pandemic R&D program to fight the threat of the deadly 2019-nCOV pandemic, how our Ii-Key technology works to generate a protective immune system response, and how fast, easy and cost effective we can manufacture Ii-Key vaccines given our vast experience in the field. We also hope to provide an update on potential opportunities on which we have been working with Chinese entities and partners to deploy our Ii-Key peptide vaccine solution in China.

As always, Generex President & Chief Executive Officer, Joseph Moscato welcomes questions from shareholders during the call.

Dial-in instructions for the investor conference call will be announced prior to the meeting date.

About Generex Biotechnology Corp. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Generex Contact:

Generex Biotechnology Corporation

Joseph Moscato646-599-6222

Todd Falls1-800-391-6755 Extension 222investor@generex.com

Continue reading here:
Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines -...

Trillium Therapeutics Inc (TRIL) is near the top in its industry group according to InvestorsObserver. TRIL gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Trillium Therapeutics Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 45 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Trillium Therapeutics Inc (TRIL) stock is lower by -2.89% while the S&P 500 has risen 0.53% as of 10:02 AM on Tuesday, Feb 11. TRIL is down -$0.10 from the previous closing price of $3.57 on volume of 168,469 shares. Over the past year the S&P 500 has risen 24.35% while TRIL has risen 179.84%. TRIL earned $2.58 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 1.34.

To see the top 5 stocks in Biotechnology click here.

Visit link:
Is Trillium Therapeutics Inc (TRIL) a Winner or a Loser in the Biotechnology Industry - InvestorsObserver

Vir Biotechnology, Inc. (NASDAQ:VIR) is one of the worst performers on the stock market today. At current price of $19.05, the shares have already lost -0.97 points (-4.85% lower) from its previous close of $20.02. Should you buy or avoid them? The stock sets an active trading volume day with a reported 105871 contracts so far this session. VIR shares had a relatively better volume day versus average trading capacity of 304.23 thousand shares, but with a 0.1 billion float and a -12.21% run over a week, its definitely worth keeping an eye on. The one year price forecast for VIR stock indicates that the average analyst price target is $26.33 per share. This means the stock has a potential increase of 38.22% from where the VIR share price has been trading recently.

Looking at the current readings for Vir Biotechnology, Inc., the two-week RSI stands at 51.22. This figure suggests that VIR stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current VIR readings is similarly very revealing as it has a stochastic reading of 28.85% at this stage. This figure means that VIR share price today is being overbought.

Technical chart claims that Vir Biotechnology, Inc. (VIR) would settle between $20.82/share to $21.62/share level. However, if the stock price goes below the $19.26 mark, then the market for Vir Biotechnology, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $18.51 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -1.67. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.

Analysts at JP Morgan lowered their recommendation on shares of VIR from Overweight to Neutral in their opinion released on February 04. Robert W. Baird, analysts launched coverage of Vir Biotechnology, Inc. (NASDAQ:VIR) stock with a Neutral recommendation, according to their flash note issued to investors on November 14. Analysts at JP Morgan, made their first call for the equity with a Overweight recommendation, according to a research note that dated back to November 05.

VIR equity has an average rating of 2.2, with the figure leaning towards a bullish end. 5 analysts who tracked the company were contacted by Reuters. Amongst them, 2 rated the stock as a hold while the remaining 3 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 3 analysts rated Vir Biotechnology, Inc. (NASDAQ:VIR) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the companys stock.

Continue reading here:
Why Shares of Vir Biotechnology, Inc. (VIR) Are -4.85% Lower Today - Find News

Lets start up with the current stock price of Puma Biotechnology, Inc. (PBYI), which is $12.33 to be very precise. The Stock rose vividly during the last session to $12.9 after opening rate of $12.8 while the lowest price it went was recorded $12.13 before closing at $12.80.

Puma Biotechnology, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $43.90 on 03/18/19, with the lowest value was $6.26 for the same time period, recorded on 11/07/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Puma Biotechnology, Inc. shares are logging -71.91% during the 52-week period from high price, and 96.96% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $6.26 and $43.90.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.68 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Puma Biotechnology, Inc. (PBYI) recorded performance in the market was 40.91%, having the revenues showcasing 64.07% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 507.13M, as it employees total of 272 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 8.82, with a change in the price was noted +0.67. In a similar fashion, Puma Biotechnology, Inc. posted a movement of +5.75% for the period of last 100 days, recording 1,989,008 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for PBYI is recording 5.48 at the time of this writing. In addition, long term Debt to Equity ratio is set at 5.48.

Raw Stochastic average of Puma Biotechnology, Inc. in the period of last 50 days is set at 65.10%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 63.92%. In the last 20 days, the companys Stochastic %K was 71.35% and its Stochastic %D was recorded 80.67%.

Bearing in mind the latest performance of Puma Biotechnology, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 40.91%. Additionally, trading for the stock in the period of the last six months notably improved by 10.48%, alongside a downfall of -53.15% for the period of the last 12 months. The shares increased approximately by 22.59% in the 7-day charts and went up by 53.36% in the period of the last 30 days. Common stock shares were driven by 64.07% during last recorded quarter.

See the original post:
Reasons Why Long-term Faith on Puma Biotechnology, Inc. (PBYI) Could Pay Off Investors - The InvestChronicle

PITTSBURGH (KDKA) Dr. Mike Hutchinson, DVM performed his first stem cell procedure in 2008. Nearly 12 years later, he can tell you all about his first case.

It was a lab mix. It couldnt get up on this floor. We tried to help it up, and it was having trouble walking so we treated it, says Hutchinson.

Fourteen days later, it came for suture removal, and it was already walking in here. He even put his front feet on the table.

Based on early success stories like that, KDKA-TV featured a 10-year-old German Shepherd named Angel.

When we met her, Angel limped noticeably from arthritis in her hips. After stem cell treatment, the dogs owner Jane Fornear says her beloved pet looked like a new dog.

Within 48 hours, her eyes were clear, explained Fornear.

She had Angel show us how much better she felt: she asked the big shepherd to sit in front of her, then told Angel, Give me your paw.

WATCH: Angels Journey To Recovery

Angel immediately lifted her right paw and put in in Fornears waiting hand about 3 feet off the ground.

Jane released the paw and said, Give me your other paw. Just as quickly, Angel lifted her left front paw off the ground and put it in Fornears other hand.

You could almost hear the tears building in Fornears voice as she petted her dogs face and ears. We couldnt give our paw before because our arms and legs hurt too much, didnt they?

Fast forward to 2014. Panzer is a large breed mix who tore the anterior cruciate ligament in one of his legs.

Dr. Mike told Panzers owner the dog would be a great candidate to use injected stem cells to help speed healing in the joint.

Sharon Germain remembers that conversation like it just happened: I just sat there going really? And I said anything to make things heal better and make him feel better. I was on board immediately.

Seven months after having the ACL repair surgery with stem cells, KDKA was there with Sharon watching Panzer tear through the November snow in Germains backyard like a hyperactive puppy.

Seeing is believing. Its just Germain paused and then let out a big sigh. It just does your heart good to see this. Germain was fully convinced it had worked for her dog.

Since those early surgeries, Hutchinson has never stopped talking about using stem cells to treat animals that are in pain.

In 2015, he told KDKA, Its just rewarding to hear from grateful pet owners over and over and over, said the Ohio State Vet School graduate. Its why I do it.

Panzer lived four years after his initial stem cell treatment. Germain said he never slowed down because his pain was gone.

It was like nothing ever happened to him. It was like he never even had surgery, says Germain. I mean, outside of a little white hair where the surgery incision was made, that was it.

Many other animals have had similar results. Hutchinson has now given stem cells to more than 1,100 animals. Many of the pets are dogs, but he has also worked with race horses as well as racing camels in the Middle East.

WATCH: Panzers Experience With Stem Cells

He has lectured and scrubbed in on stem cell surgeries around the world, Canada, South America, Australia, and across the United States.

Yet the majority of the surgeries are done at his Animal General veterinary practice in Cranberry, Butler County everyday pets like Baxter who had not one, but two torn ACLs.

They were both completely severed, explained Baxters owner Nicole Mountain of OHara Township.

He had no mobility. He had no use of his back legs. My husband Jeff was carrying him outside to use the bathroom.

Baxter is a not a little dog. He is a 95 pound Staffordshire-terrier mix. He tore those knee ligaments in 2014.

Another orthopedic vet repaired the injured joints with a procedure called PTLO surgery. It involved putting metal plates in his back legs. The Mountains were warned that it would be a long and painful recovery for their dog and for them.

(Photo Credit: KDKA)

Mountain agrees saying it was every bit as bad as they warned and then some.

Baxter was moaning in pain, Mountain says. He was pumped up with so much pain medication he was vomiting. He couldnt hold food down. He couldnt move.

Eighteen months later, Baxter was mostly healed from the surgeries, but he was still in significant pain. That is when the Mountains learned of Dr. Hutchinsons use of stem cells.

Nicole was ready to go from the moment she heard about the procedure. Her husband Jeff wasnt exactly sold.

Ill be honest, when Nicole sent us out there, I thought it was crazy. You know, I honestly did, said Jeff Mountain. I said youre sending us to this Voodoo doctor to do this stem cell treatment. I said, Where is it going to stop?'

Mountain had lived through the ordeal of helping Baxter heal from his ligament problems.

My husband was calling from Samsonite because we had one of those Help-Me harnesses, and he was lifting him up and carrying him out like luggage.

When they heard about how other dogs had been helped by stem cells, they decided to give it a try. Dr. Hutchinson recalls the conversation with the Mountains at their initial consultation.

They wanted to know if the stem cells would help the arthritis, and I said thats exactly what I would treat it with. That would be my gold therapy for that so we did that, and that had a very positive response as well. Then we were able to bank some of those cells for the future, recalls Hutchinson.

It didnt take long for the Mountains to see that Baxter was visibly better.

Within about a month, we started to really see him jumping up on counters for treats, said Jeff Mountain. You know, when we went out to walk him, he is back to running.

Mountain said that wasnt the only change she noticed.

He had this almost it sounds almost funny to say he looked very white, she paused to think. It was almost like his eyes were brighter. He was just a brighter dog. He just looked like, there was a visible difference in him.

Dr. Mike has heard it all many times.

People say it looks like their dogs are younger because their eyes are brighter. They are happier. They are in less pain, and thats a great reward for stem cells, explains Dr. Mike.

One of prospective patients first questions is often how much will it cost? When Hutchinson started, each procedure ran about $3,200. Now it has come down to about $1,800.

It can be less than that. The Mountains have a pet insurance on Baxter, and the stem cell therapy was covered by their policy.

I thought it was cost effective too, reflected Jeff Mountain, compared to other things that weve spent money on for surgeries and treatments for the dogs.

Lets go back to Panzer, Sharon Germains beloved dog. He lived nearly four years after surgery, before dying about a year ago. In retrospect knowing what she knows now, would she spend the out-of-pocket money to do stem cell treatment again on her dog?

Absolutely. Absolutely. The best money spent. Without hesitation, says Germain.

The next question: would you do it again for another dog?

Germain didnt even flinch. Absolutely. I would do it again for me.

She knows all about that too. After seeing how well it worked for her dog, she had stem cells injected into her chronically painful knee. Like her dog, she says her pain was gone in a matter of days, and it hasnt come back.

Dr. Hutchinson stresses stem cells are not a cure-all. They cant be used for every ailment, and Hutchinson says that in every lecture he does on stem cells.

I think its incumbent upon all my colleagues to be ethical and pick the right cases, says Hutchinson.

Its not a panacea. Its for certain cases. Neurological dogs, dogs that are falling over, they have nerve damage. Yeah, there might be a stem cell compassionate use for that and that might be able to help that dog, but Im not going to pretend like thats the common case.

How long do they last?

On average, it doesnt last a lifetime and it lasts maybe a year, a year and a half.

Hutchinson stopped for a second, then continued, But thats huge in a dogs life. They have a short life expectancy. So, if we get a year to year-and-a-half of comfort and pain-free time, thats fantastic. Then we can come back and re-treat them, and expect the similar response when we re-treat them.

Baxters mom Nicole Mountain agrees wholeheartedly that his quality of life is much better than it was before stem cells.

He does not get pain medication. He does not get anti-inflammatories, she claims.

He doesnt take anything thats keeping him comfortable. So for us to have something natural that will last ten, eleven months and then we do again, were thrilled with that.

Dr. Mike harvested enough cells from the original procedure on Baxter that they froze enough for multiple follow-up treatments. Because of that foresight, all they have to do is inject the thawed stem cells into Baxter. Those tune-ups cost about $200 per treatment.

Hutchinson cant say enough about what he has learned since his first stem cell surgery in 2008.

I want to do this every day in my practice because Ive been a vet for a long time, 30 plus years, and when you see the kind of results that were seeing, you know it cant be denied that any veterinarian would want to do what Im doing.

View original post here:
They Are Happier. They Are In Less Pain: Butler Co. Vet Uses Stem Cell Therapy To Help Heal Dogs - CBS Pittsburgh

A research team featuring an expert from City University of Hong Kong (CityU) has developed a novel dual approach for the first time for concurrently rejuvenating both the cardiac muscle and vasculature of the heart by utilising two types of stem cells. The results give hope for a new treatment for repairing myocardial infarction (MI) heart.

Dr Ban Ki-won, Assistant Professor of the Department of Biomedical Sciences and his research team, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology and T&R Biofab in South Korea, have conducted the first study of two distinct stem cell effects for cardiac repair. The two major types of stem cells employed are human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs). The research findings have been published in Nature Communications in a paper titled Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction.

Both cardiac muscles and vasculatures are severely damaged following MI, and so the therapeutic strategies should focus on comprehensive repair of both at the same time. But the current strategies only focus on either one, Dr Ban said.

Dr Ban said that, with limited therapeutic options for severe MI and advanced heart failure, a heart transplant was the last resort. However, such an operation is very risky, costly and subject to limited supply of suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

In the study, the hiPSC-CMs were injected directly into the border zone of the rats heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage. The results showed that this dual approach led to a significant improvement of cardiac function and an enhancement of vessel formation on a MI heart.

We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration. Based on the same principle, the protocol may also be utilised for repairing other organs including the brain, liver and pancreas in which multiple types of stem cells co-exist, Dr Ban added.

The research team is working on follow-up studies in larger animal models such as pigs. The patent application for this research result has been submitted.

Read the rest here:
First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News

Hudson Institute scientists have demonstrated for the first time that umbilical cord stem cells can protect preterm, growth-restricted babies from brain injury.

Up to five-eight percent of pregnancies in Australia are affected by fetal growth restriction (FGR)-a condition which leads to poor growth of an unborn baby.

The mechanical ventilation that these babies need for the first few days of life can have detrimental effects on the developing brain. Many of them are born early (also referred to as preterm or premature), which only exacerbates the risk of brain injury further.

This brain damage often causes long-term developmental problems, and can lead to conditions such as cerebral palsy, behavioural disorders, cognitive deficits and motor developmental delays.

There is currently no treatment which can be used as an early intervention to prevent brain damage of babies with FGR. However, a growing body of evidence suggests that stem cell therapies could be the answer to this problem.

Dr Atul Malhotra and Associate Professor Suzie Miller led a study published in Stem Cell Research and Therapy which investigated the effect of umbilical cord blood stem cells (UCBCs) in a preclinical model of FGR.

Dr Malhotra is a consultant neonatologist at Monash Newborn, Monash Childrens Hospital; a senior lecturer in the Department of Paediatrics, Monash University; and a research fellow at Hudson Institute. Associate Professor Miller is a Deputy Centre Head at Hudson Institute and a senior scientist at the Department of Obstetrics and Gynaecology, Monash University.

The team demonstrated, for the first time, that UCBCs can alleviate the brain damage caused by FGR and being born preterm-a ground-breaking discovery with significant implications for treatment.

Treatment with UCBCs led to a decrease in neuroinflammation, oxidative stress, cerebrovascular resistance (obstruction to blood flow), and greater integrity of the neurovascular unit in the brain.

The team believe that UCBCs stabilise the neurovascular unit-comprising of several different cell structures that control blood flow to the brain-possibly by reducing the inflammation surrounding them.

These UCBCs therefore act by strengthening the gate keepers of the brain, which in turn mitigates the effects of brain injury caused by an early and growth restricted birth.

We propose that the results of this study lay the foundation for a novel therapeutic option, using cord blood stem cells as an early intervention therapy for these vulnerable babies, commented Dr Malhotra.

Cell therapy is now ready for translation to clinical trials and this study provides further evidence of its potential benefit in preterm infants.

The teams next step is therefore a clinical trial of cord blood therapy in preterm babies at Monash Childrens Hospital, testing feasibility and safety of the treatment.

FGR is a condition where an unborn baby, or fetus, is smaller than expected

It can begin at any time during pregnancy, and puts babies at risk of loss in brain development, which can cause the child long-term problems in later life such as cerebral palsy, autism, learning and other behavioural challenges

Factors in the mother such as high blood pressure, diabetes, cigarette smoking and alcohol or drug use can increase the risk of FGR

The risk can also be increased by the placenta not attaching well, or blood flow through the umbilical cord being limited

Collaborators

Monash University.

Funders

National Health and Medical Research Council (NHMRC), Cerebral Palsy Alliance, The Royal Australasian College of Physicians.

Originally posted here:
Protecting growth-restricted babies from brain injury with stem cell therapy - Mirage News

Arthritis is an umbrella term for a number of conditions that cause swelling and tenderness of one or more of the joints. Osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. There's no cure for arthritis, but there are many treatments that can help slow it down and maintain quality of life, including this unusual one.

Osteoarthritis mainly affects the hands, spine, knees and hips, whereas rheumatoid arthritis usually affects the hands, feet and wrists.

Experts are researching ways to use stem cells therapy to help treat arthritis in the knee and other joints.

Many doctors already use stem cell therapy to treat arthritis, but it is not considered standard practice, with some even calling the treatment controversial.

READ MORE: Joe Swash health: I had to learn everything again Actors scary virus

There is a lot of debate around stem cell treatment and it is helpful for potential patients to understand what stem cells are and the issues surrounding their use in arthritis therapy.

How the treatment could help is by reducing inflammation in the body.

In arthritis, the immune system mistakenly attacks the tissue that lines the joints, which causes pain, inflammation, swelling and stiffness.

By reducing inflammation, stem cell therapy increases the presence of healthy cells in the body.

DONT MISS

And it would seem that stem cell therapy has sparked some interest from the royal family.

Princess Michael of Kent, the wife of the Queens cousin Prince Michael, recently appeared in a slick promotional video for a clinic in the Bahamas that offers similar joint therapy.

Look at that, the Princess declares proudly in the five-minute film, holding her right arm high above her head after stem-cell injections for a painful shoulder.

"Its amazing I think stem cells are the future, theres no doubt in my mind."

A stem cell is a type of cell not specialised to perform a specific role.

Instead, it has the unique ability to develop into one of many different types of cell. Stem cell therapy uses stem cells to replace dead and diseased cells within the body.

The human body contains over 200 different types of cell. Usually, each type has certain characteristics that allow it to preform a specific role.

Cells with similar roles group together to form tissues, which then organise to form the bodys organs.

Scientists source the stem cells from body tissue, either from an embryo or an adult human and isolate them in the laboratory.

After manipulating the cells to develop into specific types, they then inject the cells into the recipients blood or tissue.

Researchers are still investigating ways of using stem cells to control inflammation and regenerate damaged tissues.

Mesenchymal stem cells (MSCs) are types of stem cell that can develop into cartilage and bone. Synovial MSC therapy involves injecting these cells directly int the tissues surrounding the affected joints.

Some research shows that MSCs are also able to suppress the immune system and reduce the bodys inflammatory response.

This makes MSC therapy a promising treatment option for autoimmune conditions such as arthritis.

But for all the positive evidence supporting the treatment, it remains hugely controversial.

Most specialists say there is little robust evidence to show it works and it has not been approved by the UK medicines regulator, the National Institute for Health and Care Excellence. Leading health experts most standard approaches to treating arthritis is advising patients to lose weight and get more exercise.

In the US, Google has banned all advertising for products that contain stem cells or another regenerative therapy which uses blood cells, known as platelet-rich plasma, or PRP, because regulators describe the treatments as "new and exploratory".

And in the UK, experts have rubbished claims that Lipogems can treat arthritis.

Professor Chinmay Gupte, consultant orthopaedic surgeon and senior lecturer in knee surgery at Imperial College London, warns: These are extremely expensive treatments, and largely unproven. The problem is when youre desperate, youll try anything.

Read the rest here:
Arthritis treatment: A controversial treatment promoted by a certain royal could help - Express

KEY POINTS

Arthritis is one of the most painful diseases around. Patients would often be taking pain relievers just to combat pain. There are those who seek doctors and are given over-the-counter medications, and there are also those who go the natural means. One royal is promoting a certain kind of treatment, and while the said treatment may have been dubbed as a controversial one, health experts say that it might just help.

The Use of Stem Cells

Stem cell treatment may be the next big thing when it comes to treating arthritis. As per Express report, a lot of doctors have already started using stem cell therapy to treat the debilitating disease. Although it is not considered as a standard practice, with many calling the treatment as controversial, it would seem that more people are going this way. stem cell treatment arthritis Photo: darkostojanovic - Pixabay

This type of treatment reduces inflammation in the body. When inflammation is kept at bay, pain is likewise reduced, allowing patients to suffer less from the disease. This kind of therapy helps in increasing the number of healthy cells.

The Royal Princess

According to the report of Express, Princess Michael of Kent, the wife of Prince Michael, who is the Queens cousin, recently appeared in an ad. In the said promotional video, the Princess was showing her right arm, signifying that stem cells are the future.

She had stem cell injections for the painful shoulder. The video was for a clinic in the Bahamas that offers the arthritis stem cell treatment.

Stem Cell and Arthritis

Researchers are still looking for ways on how to use stem cells to regenerate tissues and to control inflammation. The mesenchymal stem cells (MSCs) are the types of stem cells that develop into cartilage and bone. This has shown great promise in treating arthritis.

Despite the positive responses that the treatment has, there are still those who doubt it and would consider it as controversial. As for those who have benefited from the treatment, maybe stem cells did wonders for them. It could be an avenue for those who are still looking for effective arthritis treatment.

Read the rest here:
Arthritis Treatment: One Royal Is Promoting A Certain Kind Of Treatment - International Business Times

The Stem Cell Therapy Market report 2020-2026 provides a comprehensive analysis of the current market for Smart Camera. It determines the market size of Stem Cell Therapy and also determines the factors that control market growth. The report begins with a basic overview of the Stem Cell Therapy industry and then goes into the Details of the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

The Stem Cell Therapy market report provides detailed information on key factors, Opportunities, Challenges, industry trends and their impact on the market. The market report Stem Cell Therapy also includes company data and its operation. This report also contains information about the pricing strategy, brand strategy and target customer of the Stem Cell Therapy market. It also provides the distributors/dealer list offered by the company. This research report also deals with the main competition, the market development with forecast of the expected years and the expected growth rates. The main factors that drive and influence growth market data and analysis come from a combination of primary and secondary sources.

Get | Download Sample Copy @https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=JLN&utm_medium=002

[Note: our free sample report provides a brief introduction to the table of contents, table of contents, list of tables and figures, competitive landscape and geographic segmentation, as well as innovations and future developments based on research methods.]

The top Manufacturer with company profile, sales volume, and product specifications, revenue (Million/Billion USD) and market share

Global Stem Cell Therapy Market Competitive Insights

The competitive analysis serves as a bridge between manufacturers and other participants that are available on the Stem Cell Therapy Market. The report includes a comparative study of Top market players with company profiles of competitive companies, Stem Cell Therapy Market product innovations and cost structure, production sites and processes, sales details of past years and technologies used by them. The Stem Cell Therapy Market report also explains the main strategies of competitors, their SWOT analysis and how the competition will react to changes in marketing techniques. In this report, the best market research techniques were used to provide the latest knowledge about Stem Cell Therapy Market to competitors in the market.

Global Stem Cell Therapy Market Segmentation information

The report provides important insights into the various market segments presented to simplify the assessment of the global Stem Cell Therapy Market. These market segments are based on several relevant factors, including Stem Cell Therapy Market product type or services, end users or applications and regions. The report also includes a detailed analysis of the regional potential of the Stem Cell Therapy Market, which includes the difference between production values and demand volumes, as well as the presence of market participants and the growth of each Region over the given forecast period

Ask For Discount (Exclusive Offer) @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=JLN&utm_medium=002

Stem Cell Therapy Market: Regional Analysis :

As part of regional analysis, important regions such as North America, Europe, the MEA, Latin America, and Asia Pacific have been studied. The regional Stem Cell Therapy markets are analyzed based on share, growth rate, size, production, consumption, revenue, sales, and other crucial factors. The report also provides country-level analysis of the Stem Cell Therapy industry.

Table of Contents

Introduction: The report starts off with an executive summary, including top highlights of the research study on the Stem Cell Therapy industry.

Market Segmentation: This section provides detailed analysis of type and application segments of the Stem Cell Therapy industry and shows the progress of each segment with the help of easy-to-understand statistics and graphical presentations.

Regional Analysis: All major regions and countries are covered in the report on the Stem Cell Therapy industry.

Market Dynamics: The report offers deep insights into the dynamics of the Stem Cell Therapy industry, including challenges, restraints, trends, opportunities, and drivers.

Competition: Here, the report provides company profiling of leading players competing in the Stem Cell Therapy industry.

Forecasts: This section is filled with global and regional forecasts, CAGR and size estimations for the Stem Cell Therapy industry and its segments, and production, revenue, consumption, sales, and other forecasts.

Recommendations: The authors of the report have provided practical suggestions and reliable recommendations to help players to achieve a position of strength in the Stem Cell Therapy industry.

Research Methodology: The report provides clear information on the research approach, tools, and methodology and data sources used for the research study on the Stem Cell Therapy industry.

What will you find out from the global Stem Cell Therapy Market Report?

The report contains statistical analyses of the current and future Status of the global Stem Cell Therapy Market with a forecast to 2026.The report contains detailed information on manufacturers, Stem Cell Therapy Market raw material suppliers and buyers with their trade outlook for 2020-2026.The report informs you about the most important drivers, technologies and Trends that will shape the global Stem Cell Therapy Market in the near future.The report added an exclusive market segmentation, broken down by Product Type, Stem Cell Therapy Market end user and Region.The strategic perspectives on Stem Cell Therapy Market Dynamics, current production process and applications.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=JLN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Our research studies help our clients to make superior data-driven decisions, capitalize on future opportunities, optimize efficiency and keeping them competitive by working as their partner to deliver the right information without compromise.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email:[emailprotected]

Read the original here:
Stem Cell Therapy Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2026 - Jewish Life News

Global Marketers.biz has published an innovative statistics of the market titled as Stem Cell Therapy Market. To clarify the various aspects, the analyst studies and elaborates the terms by using qualitative and quantitative research techniques. Finance teams can use a variety of corporate planning applications to fulfil the budgeting, planning & financial modelling, needs of their organization, whatever its size, industry and location.

Download Exclusive Sample of Stem Cell Therapy Markets Premium Report at: https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #request_sample

Graphs, tables, bar graphs and pie charts have been represented in sophisticate manner for the clients to better understand the analysis. To enlarge the businesses, customers get increased rapidly through Stem Cell Therapy industry techniques.

Leading Establishments (Key Companies): Osiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCRPharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Different regions, such as Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey and GCC Countries are focused to give the summarized data about the production of Stem Cell Therapy market.

The global Stem Cell Therapy Market is served as a backbone for the enlargement of the enterprises. To address the challenges, the report examines different key factors such as drivers and opportunities. Restraints are considered for evaluation of risk in market.

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and analyses the market trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Global Marketers.biz have segmented the Stem Cell Therapy market on the basis of type, end-user and region:

Inquiry Here For Detail Report @ https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #inquiry_before_buying

Type Outlook (Revenue in Million USD; 20152026)

AutologousAllogeneic

End Use Outlook (Revenue in Million USD; 20152026)

Musculoskeletal DisorderWounds & InjuriesCorneaCardiovascular DiseasesOthers

Stem Cell Therapy Market Summary: This report includes the estimation of market size for value (million US$) and volume. Estimation methodology validate the market size of Stem Cell Therapy industry, to estimate the size of various other dependent submarkets in the overall market. Secondary research is used to identify the top players in the market, and their market shares have been determined through primary and secondary research. Each type is studied based on classification as Sales, Stem Cell Therapy Market Share (%), Revenue (Million USD), Price and Gross Margin.

Report Objectives:

Target Audience:

Table of Content:

To know More Details About Stem Cell Therapy Market research Report @: https://www.globalmarketers.biz/report/medicine/global-stem-cell-therapy-market-2019-by-company,-regions,-type-and-application,-forecast-to-2024/130793 #table_of_contents

***Thanks for reading! You can also request custom information like chapter-wise or specific region-wise study as per your interest. ***

View post:
Stem Cell Therapy Market is poised to achieve continuing growth During Forecast Period 2020-2026 - Jewish Life News

The Research Report on Stem Cell Therapy marketis a Skillful and Deep Analysis of the Present Situation and Challenges. Experts have studied the historical data and compared it with the current market situation. The Research Reportcovers all the necessary information required by new market entrants as well as the existing players to gain a deeper insight into the market.

Moreover, the research study focuses on the product specifications, diversification, price, cost, production capacity, distribution channel, list of the distributors, and a profound analysis of the import and export data of the product. Upstream raw materials, downstream demand analysis together with the cost, supplier, and consumer list of this market have been examined consistently; product flow and marketing channel have been mentioned as well.

Get a Sample Copy of this Report @:https://www.reportsmonitor.com/request_sample/853193

TheMajor Manufacturers Covered in this Report:Osiris Therapeutics, Inc., Medipost Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate Srl, Jcr Pharmaceuticals Co., Ltd., Nuvasive, Inc., Rti Surgical, Inc., Allosource

The research study focuses on

Type Segmentation (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy)Industry Segmentation (Musculoskeletal Disorders, Wounds And Injuries, Cardiovascular Diseases, Surgeries, Gastrointestinal Diseases)

On the basis of geographical segmentation, the report has been categorized into some of the major regions, with production, generation, revenue, usage, aggregate share and the development rate of the market in these geographies over the forecast period, including North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Regional Segmentation:

Speak to our industry expert and avail discount on Market [emailprotected]https://www.reportsmonitor.com/check_discount/853193

Some of the Points cover in Global Stem Cell TherapyMarket Research Report is:

Chapter 1: Overview of Global Stem Cell TherapyMarket (2020 2024) Definition Specifications Classification Applications Regions

Chapter 2: Market Competition by Players/Suppliers (2020 2024) Raw Material and Suppliers Manufacturing Process Industry Chain Structure.

Explore Full Report with Detailed TOC, Charts, Tables and [emailprotected]https://www.reportsmonitor.com/report/853193/Stem-Cell-Therapy-Market

The key takeaways from the report:

Contact Us:Jay MatthewsDirect: +1 513 549 5911 (U.S.), +44 203 318 2846 (U.K.)Email: [emailprotected]

Go here to read the rest:
Stem Cell Therapy Market Is Changing Drastically? What If History Is Any Guide 2020-2024 | Osiris Therapeutics, Inc., Medipost Co. etc. - Science...

CALGARY, Alberta, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Hemostemix Inc. (Hemostemix or the Company) (TSXV: HEM; OTC: HMTXF) is pleased to announce the appointment of Dr. Ronnie Hershman, M.D., F.C.C.S., to its Board of Directors. Dr. Hershman is a successful, practicing cardiologist with over three decades of experience. Dr. Hershman graduated Magna Cum Laude from the Sophie Davis Center for Biomedical Research in 1980 and received his medical degree from Mount Sinai Medical Center in 1982. He then continued his medical and cardiovascular training at Mt. Sinai Medical Center.

Dr. Hershman has been an Invasive Cardiologist since 1987 and was involved in many clinical trials for emerging catheter technologies. He was a pioneer in performing laser-assisted coronary angioplasty, starting in private practice on Long Island in 1989. Presently the Medical Director of NYU Langone Long Island Cardiac Care he built and manages a large medical practice, employing cutting-edge technology and continues his practice for patients with cardiovascular and peripheral vascular diseases, employing a non-invasive therapy for patients with intractable Angina and Congestive Heart Failure.

Dr. Hershman has also been an entrepreneur and investor for more than two decades. He has been involved in life science investing and consulting for several years and previously or currently serves on the boards of medical biotechnology companies Solubest, Ltd., TheraVitae Inc., Nasus Pharma, SanoNash and Optivasive. He also serves as an advisor to a latestage, life science venture capital company that has funded 24 companies to-date. Dr. Hershman is now an investor in OurCrowd, Ltd., a leading crowd funding company and is the Co-Founder and CEO of HealthEffect, LLC and CLiHealth, LLC, SoLoyal and Nasus Pharma along with SanoNash.

Dr. Hershman continues to evaluate new medical technologies in the USA and Israel. His main interests lie in bringing improved medical technologies from the bench to the clinic, quickly and globally. He is actively seeking to commercialize technologies that improve lives and cure illnesses in the most effective and cost efficient manner.

Stem Cell therapies are the future in so many chronic illnesses and Hemostemix is an exciting company with a lot of promise in providing solutions and therapeutic options for many patients with critical Cardiovascular illnesses and ischemia, commented Dr. Hershman. As an investor and Board Member, I hope to assist in advancing these therapies further and create optimal value for patients and shareholders, alike, he said.

Dr. Hershman is replacing Mr. Yari Nieken and Mr. Bryson Goodwin who both resigned from their positions with the Company effective February 10, 2020. Ms. Natasha Sever has also resigned from the position of CFO. The Company will look for suitable replacements for both CEO and CFO positions and Mr. Smeenk will act as the interim CEO until a replacement is hired. The Company thanks Bryson, Yari and Natasha for their service and wishes them well in their future endeavors.

It is a great pleasure to welcome Dr. Hershman to the Board of Directors, said David Wood, Chairman, as he compliments us with his broad medical experience, biotechnology and business investment acumen and counsel.

I am honored and delighted to welcome Dr. Hershman to the Board of Directors and I very much look forward to his counsel, said Thomas Smeenk, President.

The Company also announces that on January 9, 2020, J.M. Wood Investment Inc. (JMWI) sent the Company a Notice of Default and Demand for the immediate repayment of the Companys previously announced convertible debenture and demand loan. Based on the repayment conditions of the debts, the Company took the position the January 9th notice was premature. On January 24th, JMWI made an application to the Court of Queens Bench of Alberta for the issuance of an order appointing a receiver. The Company responded with a 347 page affidavit including appendices, sworn on January 30th by David Wood, Chairman. The application was heard on January 31st by Madame Justice Horner, who granted a consent order to adjourn the JMWI receivership application to February 20, 2020 to enable the Company to close its financing; granted an order appointing Grant Thornton as inspector; granted an order that the costs of the application of January 31st would only be payable by the Company if the application proceeds on February 20th. On February 6, 2020 cross examinations on the Affidavits of David Wood and JMWI were heard.

Story continues

Also, on February 3, 2020 the Company received an action from Aspire Health Science, LLC filed with the Ninth Judicial Circuit Court for Orange County, State of Florida, in connection with the Amended and Restated License Agreement rescinded by Hemostemix on December 5, 2019 due to Aspires failure to meet the Condition Precedent of paying US$1,000,000 within 30 business days of September 30, 2019. The Company believes the action is frivolous, without merit, and it intends to vigorously defend its position.

The Company intends to effect repayment of the secured debts and it will provide a further update to the market at that time. Although the Company is optimistic that it will be successful in raising sufficient funds to meet its obligations, there can be no assurance that the financing will close as anticipated or within the time frames required.

ABOUT HEMOSTEMIX INC.

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other heart conditions. ACP-01 has been used to treat over 300 patients, including no-option end-stage heart disease patients, and it has been the subject of four open label phase II clinical studies which proved its safety and efficacy.

On October 21, 2019, the Company announced the results from its presentation from its Phase II CLI trial abstract presentation entitled Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Companys clinical trial for CLI is ongoing at 20 clinical sites in North America and 56 of 95 subjects have been enrolled to-date.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact:

Thomas Smeenk, President & CEO Suite 1150, 707 7th Avenue S.W.Calgary, Alberta T2P 3H6Tel: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words expects, plans, anticipates, believes, intends, estimates, projects, potential, and similar expressions, or that events or conditions will, would, may, could, or should occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. By their nature forward-looking statements are subject to known and unknown risks, uncertainties, and other factors which may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the Companys ability to fund operations and access the capital required to continue operations and repay its secured debts, the Companys stage of development, the ability to complete its current CLI clinical trial, complete a futility analysis and the results of such, future clinical trials and results, long-term capital requirements and future developments in the Companys markets and the markets in which it expects to compete, risks associated with its strategic alliances and the impact of entering new markets on the Companys operations. Each factor should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise. Additional information identifying risks and uncertainties are contained in the Companys filing with the Canadian securities regulators, which filings are available at http://www.sedar.com.

Excerpt from:
Hemostemix Announces the Appointment of Dr. Ronnie Hershman to the Board of Directors and Provides a Corporate Update - Yahoo Finance

To save this word, you'll need to log in.

: a branch of medical science dealing with the structure, functions, and diseases of the eye

These example sentences are selected automatically from various online news sources to reflect current usage of the word 'ophthalmology.' Views expressed in the examples do not represent the opinion of Merriam-Webster or its editors. Send us feedback.

circa 1842, in the meaning defined above

borrowed from German Ophthalmologie, from ophthalmo- ophthalmo- + -logie -logy

Cite this Entry

Ophthalmology. Merriam-Webster.com Dictionary, Merriam-Webster, https://www.merriam-webster.com/dictionary/ophthalmology. Accessed 10 Feb. 2020.

More Definitions for ophthalmology

: a branch of medical science dealing with the structure, functions, and diseases of the eye

Other Words from ophthalmology

Comments on ophthalmology

What made you want to look up ophthalmology? Please tell us where you read or heard it (including the quote, if possible).

Read the original here:
Ophthalmology | Definition of Ophthalmology by Merriam-Webster

Learn more about Ophthalmology Specialists

Anoptometristis a healthcare provider who specializes in routine and preventive eye and vision care. Optometrists diagnose vision abnormalities and prescribe eyeglasses and contacts. They detect and treat cataracts, glaucoma, and eye infections. Optometrists also screen for conditions that affect the eyes and vision, includinghigh blood pressureand diabetes.

An optometrist typically:

Evaluates a patients medical and vision history

Educates the patient about eye and vision disease prevention and health

Performs a comprehensive eye and vision exam and evaluates blood pressure

Performs and interprets specialized eye tests

Diagnoses and often treats acute and chronic eye diseases and conditions that affect vision, including eye injuries, vision problems, cataracts, and glaucoma

Screens for conditions that increase the risk of eye and vision conditions including diabetes and high blood pressure

Prescribes eye glasses, contacts, and certain medications

Refers patients to an ophthalmologist for serious eye problems and most eye surgeries

Performs laser or glaucoma surgeries in some cases

Provides eye and vision care before and after eye surgery

An optometrist may also be known by the following names:eye doctor, vision care specialist, and Doctor of Optometry (OD).

There are 743 specialists practicing Ophthalmology in New Jersey with an overall average rating of 4.1 stars. There are 111 hospitals in New Jersey with affiliated Ophthalmology specialists, including Valley Hospital, Saint Barnabas Medical Center and Clara Maass Medical Center.

Original post:
New Jersey Ophthalmology - City Directory

In the past, there was a substantial growth in the elderly population and the occurrence of the disorders related to age, involves eye disorders. Opthalmology PACS is the main factor fueling the demand for the inventive technologies for the treatment and diagnosis of the ophthalmic conditions driving the ophthalmology PACS market. Layer of tear is losing the stability and damages rapidly in the geriatric population, as a result, risk of having the severe eye disorders are increasing substantially with age after 60 years. These eye disorders are involving the conditions like cataract, diabetic eye disease, glaucoma, low vision and macular degeneration.

Request a sample of this report @https://www.adroitmarketresearch.com/contacts/request-sample/608

Most of the people with the eye diseases are increasing worldwide, and the loss of vision is the main concern amongst the individuals. Increase in the occurrence of the chronic diseases like hypertension, diabetes and aging population are increasing the occurrence of the eye disorders like ocular hypertension and diabetic retinopathy are boosting the global ophthalmology PACS market. Maximum blind population or those suffering from less vision is anticipated to grow significantly and increase the ophthalmology PACS market share. Opthalmology PACS are efficiently used in the production of the image data eradicating the physical restraints related to the communication of the radiologic image on film.

Increase in the occurrence of the eye disorders is creating it habitual for the ophthalmologists to instruct the unique methods of treatment. Various regions are having the high rate of accepting the ophthalmology PACS because of the increase in awareness amongst the healthcare professionals and the general population. Factors that are responsible for the growth of ophthalmology PACS market are shortage of ophthalmologists, increase in the acceptance of teleophthalmology, increase in the eye diseases and growth in the elderly population. Although, implementing the PACS is of high price, more training required, fault in the system results in the loss of images are the drawbacks that are hampering the global ophthalmology PACS market growth. PACS is the picture archiving and communications system (PACS) referring a computer system that are displaying, capturing and storing medical images. Integrated PACS are having various advantages like cost-effectiveness, data security, reliability, use and easy establishment. PACS are analyzing and manipulating the image, provides effective data management and transport and saves the cost of printing, lessen the waiting time for patients. These advantages are playing the major role for accepting the PACS and are fueling the growth of ophthalmology PACS market.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market

Global ophthalmology PACS market is segmented into end-use, type, delivery model and region. On the basis of end-use, market is divided into hospitals, Ambulatory Surgical Center (ASCS) & Specialty Clinics and more. Based on type, market is divided into standalone PACS and integrated PACS. On considering the delivery model, market is divided into cloud/ web based models, on-premise models and more.

Geographically, regions involved in the development of global ophthalmology PACS market share are Europe, North America, Asia Pacific and Latin America. North America is anticipated to hold the largest ophthalmology market share in the coming future. Asia Pacific is estimated to grow at the highest CAGR over the forecast period.

Key players involved in increasing the global ophthalmology PACS market size are Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Key Segments in the Global Ophthalmology PACS Market are-

By End-Use, market is segmented into:

Hospitals

Ambulatory Surgical Center (ASCS) & Specialty Clinics

Others

By Type, market is segmented into:

Standalone PACS

Integrated PACS

By Delivery Model, market is segmented into:

Cloud/ web based models

On-premise models

Others

By Regions market is segmented into:

Europe

North America

Asia-Pacific

Latin America

What to expect from the Global Ophthalmology PACS Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Enquire for in-depth information before buying this report @https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Info:

Ryan Johnson

Adroit Market Research

3131 McKinney Ave Ste 600,

Dallas, Texas 75204, U.S.A

Phone No: + +19723628199

Email:[emailprotected]

The rest is here:
Opthalmology Pacs Market 2020 Size by Top Global Leading Players, Opportunities, Revenue Growth, Trends, Outlook and Forecasts to 2025 - TechNews.mobi

Chittagong Eye Infirmary and Training Complex (CEITC) celebrated its 47th anniversary at its complex at the port citys Foys Lake on Saturday.

The celebration of the complex rendering service in eye care, which has been in place since 1973, began through the seminar on "Community Opthalmology" on Saturday morning.

Nine renowned personalities, who contributed to education and health, were honoured with gold medals.

National professor Dr Jamilur Reza Chowdhury handed out the medals to the awardees.

They included: Dr Frank Billson, a professor at the University of Sydney who fought against avoidable blindness in Asia-Pacific region; Dr Thulasiraj Ravilla, a renowned ophthalmologist of India and Bob Ranck, chief executive of Orbis International.

Besides, internationally-acclaimed childrens rights hero Rosi Gollmann, Dr R Pararajasegaram, famous opthalmologist of Sri Lanka; Dr Zafrullah Chowdhury, founder of Gonoshastha Kendra, and national professor Dr Abdul Malek, a prominent cardiologist of Bangladesh, were honoured at the ceremony.

Apart from the aforementioned, two posthumous honours were also conferred the late Zahur Ahmed Chowdhury, a former minister of health, labour and social welfare and the late professor MA Matin, also a former minister.

Dr Jamilur Reza Chowdhury, chief guest at the programme, said, "The small step taken in 1972 has now become a great shelter for people in need of eyecare. Thousands of students were trained in specialised eyecare from CEITC. They are playing a great role in fighting visual impairment," he added.

He urged CEITC to work to increase the number of eye donors as it was very small in proportion to the country's population.

Mahfuz Anam, editor of The Daily Star, also took part in the anniversary and visited the newly-built Imperial Hospital with Dr Robiul Hossain, managing trustee of CEITC.

MA Malek, editor and publisher of local Daily Azadi, chaired the second session of the anniversary.

Professor Shireen Akther, vice-chancellor of Chattogram University, Mahtab Uddin Chowdhury, president of Awami League, city unit and Sufi Mohammad Mizanur Rahman, chairman of PHP family were present among others.

See the rest here:
Celebrating 47th anniversary of CEITC - The Daily Star

Dublin, Feb. 10, 2020 (GLOBE NEWSWIRE) -- The "Camera Modules Market by Component (Image Sensors, Lens Modules, Voice Coil Motors), Focus Type (Fixed, Auto), Interface, Pixel, Process, Application (Consumer Electronics, Automotive, Security & Surveillance), and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global camera modules market size is projected to grow from USD 31.5 billion in 2020 to USD 44.6 billion by 2025, recording a CAGR of 7.2%.

Increasing trends of multiple camera-based smartphones to drive camera modules market.

Rising public safety and security concerns led to the adoption of surveillance cameras, technological advancements in components of camera modules for its integration in devices, and rising demand for ToF cameras in smartphones are driving the growth of the camera modules industry. However, constraints such as high cost of multi-camera systems deployment in vehicles may hinder the market growth.

Consumer electronics to be largest market for camera modules throughout forecast period.

Consumer electronics is one of the highly competitive industries which observes rapid technological advancements due to continuous change in consumer demands. Smartphones derive significantly higher market for camera modules in consumer electronics applications due to the increasing trend of multiple camera smartphones. To improve functionality and quality of images produced by smartphones and rising trends of front cameras, OEMs are shifting from single rear cameras to dual, triple, and quad-camera designs, resulting in increasing adoption of an average number of camera modules per smartphone.

For instance, in September 2019, Apple launched a new range of iPhones, including iPhone 11, iPhone 11 Pro, and iPhone 11 Pro Max. iPhone 11 features dual camera, each having 12 MP resolution while iPhone 11 Pro and iPhone Pro Max feature triple cameras, each with 12 MP resolution. Other leading smartphone OEMs such as Samsung, Xiaomi, and Huawei are introducing smartphones featuring multiple cameras. Xiaomi is already set to introduce Mi Note 10 in early 2020 with a 108 MP rear camera among 4 other rear cameras. These developments are expected to play an important role in the growth of the camera modules market during the forecast period.

APAC to record highest growth rate during forecast period.

APAC is likely to be the fastest-growing region for the camera modules market in the coming years. The factors contributing to the significant growth rate of APAC in camera modules market, along with the largest market share, include the presence of leading smartphone manufacturers such as Samsung, Huawei, Oppo, and Xiaomi. Smartphones assist consumer electronics applications to constitute a significant share in the camera modules market.

China is a base for several camera modules as well as consumer electronics products manufacturers. Different camera-related smartphone trends in the country are expected to draw new opportunities for the camera modules market. Several factors, such as government mandates based on the autonomy of vehicles in China, will assist camera modules market to propel. Automotive players in Japan are introducing new safety functions using camera modules, which is expected to induce high market growth.

Key Topics Covered

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights 4.1 Attractive Opportunities in Camera Modules Market4.2 Market in APAC, By Component and Application4.3 Camera Module Market, By Interface4.4 Country-Wise Camera Modules Market Growth Rate

5 Market Overview 5.1 Introduction5.2 Value Chain Analysis5.3 Market Dynamics5.3.1 Drivers5.3.1.1 Increasing Trends of Multiple Camera-Based Smartphones5.3.1.2 Rising Public Safety and Security Concerns Lead to Adoption of Surveillance Cameras5.3.1.3 Technological Advancements in Components of Camera Modules for Integration in Devices5.3.1.4 Rising Demand for Tof Camera in Smartphones5.3.2 Restraints5.3.2.1 High Cost of Multi-Camera Systems Deployment in Vehicles5.3.3 Opportunities5.3.3.1 Government Initiatives to Increase Vehicle Safety is Leading to Adoption of ADAS5.3.3.2 Emergence of Autonomous Vehicles5.3.3.3 Growing Applications of AR and VR Devices5.3.4 Challenges5.3.4.1 Managing Image From Multiple Cameras in Smartphone May Limit Processing Power

6 Camera Modules Market, By Component 6.1 Introduction6.2 Image Sensors6.2.1 CMOS Image Sensors6.2.1.1 Frontside Illumination (FSI) Technology6.2.1.1.1 Manufacturing Process of FSI is Simple and Low-Cost6.2.1.2 Backside Illumination (BSI) Technology6.2.1.2.1 Increasing Adoption of Higher Megapixel Cameras in Various Applications to Drive the Growth of Market6.2.2 CCD Image Sensors6.2.2.1 CCD Image Sensors are Used in Professional, Medical, and Scientific Applications6.2.3 Other Image Sensors6.2.3.1 NMOS Image Sensors6.2.3.2 InGaAs Image Sensors6.2.3.3 sCMOS Image Sensors6.3 Lens Modules6.3.1 Consumer Applications Hold Major Share of Camera Lens Modules Market6.4 Voice Coil Motors6.4.1 APAC to Provide Opportunities for VCM Market Owing to Presence of Large Number of OEMs6.5 Other Components

7 Camera Modules Market, By Focus Type 7.1 Introduction7.2 Fixed Focus7.2.1 Growth is Driven By Increasing Adoption of Cameras in Automotive and Surveillance Applications7.3 Autofocus7.3.1 Emerging Applications Such as Robotics, Drones, ARtificial Intelligence, and Wearables Would Provide Growth Opportunities

8 Camera Modules Market, By Interface 8.1 Introduction8.2 Camera Serial Interface8.2.1 Better Performance of CSI to Provide Growth Opportunity Formarket8.3 Camera Parallel Interface8.3.1 APAC to Create Opportunities for Camera Modules With Parallel Interface

9 Camera Modules Market, By Pixels 9.1 Introduction9.2 Up to 7 MP9.2.1 ADAS and Smartphones Provide Opportunity for Market9.3 8 to 13 MP9.3.1 Rising Trends of Multiple and High Megapixel Camera-Based Smartphones to Driver Market Growth9.4 Above 13 MP9.4.1 Technological Advancements in Smartphones and Demand for Better Image Quality Would Propel Market Growth

10 Camera Modules, By Process 10.1 Introduction10.2 Flip-Chip Camera Module10.3 Chip-On-Board Camera Module

11 Camera Modules Market, By Application 11.1 Introduction11.2 Consumer Electronics11.2.1 Smartphones11.2.1.1 OEM's Shift From Single Rear Cameras to Dual, Triple, and Quad Camera Designs in Smartphones Drives Market11.2.2 Tablet PC11.2.2.1 Rising Adoption of Tablet PCS to Create Opportunity for Market11.2.3 Camera11.2.3.1 Rising Interests of Consumers for Photography to Drive Growth of Market11.2.4 Wearable11.2.4.1 Emerging Technologies Such as AR and VR to Provide Opportunity for Market11.2.5 Others11.3 Automotive11.3.1 By Function11.3.1.1 ADAS11.3.1.1.1 Stringent Government Regulations to Boost Adoption of Automotive Cameras11.3.1.2 Viewing11.3.1.2.1 Rising Trends of OEMs to Provide Advanced Technologies in Vehicle to Drive Growth of Market11.3.2 By View Type11.3.2.1 Rear View11.3.2.1.1 APAC to Grow at Highest CAGR for Camera Modules Market for Rear View Application11.3.2.2 Front View & Others11.3.2.2.1 Camera Modules Market to Grow at Higher Rate for Front View & Other Applications11.3.3 By Vehicle Type11.3.3.1 Passenger Car11.3.3.1.1 Passenger Car Segment to Dominate Camera Modules Market11.3.3.2 Commercial Vehicles11.3.3.2.1 North America to Lead Camera Modules Market for Commercial Vehicles During Forecast Period11.4 Healthcare11.4.1 Endoscopy11.4.1.1 Technological Advancements in Healthcare Industry to Drive Market Growth11.4.2 Opthalmology11.4.2.1 Increasing Adoption of Imaging Technology in Medical Applications to Provide Opportunity for Market11.4.3 Others11.5 Industrial11.5.1 Machine Vision11.5.1.1 Rising Industrial Automation and Adoption of Industrial IoT Solutions Trends Provide Growth Opportunities11.5.2 Robotic Vision11.5.2.1 Increasing Adoption of Advanced Technologies in Industrial Manufacturing to Create Growth Opportunity for Market11.6 Security & Surveillance11.6.1 Public Places & Infrastructures11.6.1.1 Increasing Government Projects of Smart Cities to Provide Opportunity for Market11.6.2 Commercial & Residential11.6.2.1 Increasing Safety and Security Concerns to Drive Market Growth11.7 Aerospace & Defense11.7.1 Airborne and Marine Surveillance11.7.1.1 Rising Adoption of Cameras for Aerial Vehicles to Provide Opportunity for Market11.7.2 Border Surveillance & Military Operations11.7.2.1 Increased Border Surveillance By Governments to Drive Market

12 Geographic Analysis 12.1 Introduction12.2 North America12.3 Europe12.4 APAC12.5 Rest of the World

13 Competitive Landscape 13.1 Overview13.2 Market Ranking Analysis13.2.1 Product Launches and Developments13.2.2 Agreements, Partnerships, and Collaborations13.2.3 Expansions13.2.4 Acquisitions13.3 Competitive Leadership Mapping13.3.1 Visionary Leaders13.3.2 Innovators13.3.3 Dynamic Differentiators13.3.4 Emerging Players

14 Company Profiles 14.1 Introduction14.2 Key Players14.2.1 LG Innotek14.2.2 Sunny Optical Technology (Group)14.2.3 Sharp14.2.4 Samsung Electro-Mechanics14.2.5 OFILM Tech14.2.6 AMS14.2.7 Chicony14.2.8 MCNEX14.2.9 Primax Electronics14.2.10 Q Technology14.3 Right to Win14.4 Other Key Players14.4.1 CAMMSYS14.4.2 Cowell14.4.3 E-Con Systems14.4.4 Haesung Optics14.4.5 Jenoptik14.4.6 Kyocera14.4.7 Leopard Imaging14.4.8 Luxvisions Innovation Limited14.4.9 Partron14.4.10 Shenzhen CM Technology Company Ltd.14.4.11 Truly Opto-Electronics

Story continues

For more information about this report visit https://www.researchandmarkets.com/r/n7ill5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

Read more:
Global Camera Modules Market Worth $44.6 Billion by 2025 - Increasing Trends of Multiple Camera-Based Smartphones, Growing Applications of AR and VR...

Back in the thirties we were told we must collectivize the nation because the people were so poor. Now we are told we must collectivize the nation because the people are so rich. William F. Buckley Jr.

Today, we revisit a 'Tier 3' biotech stock whose stock has been under some recent pressure. However, it has two potential significant catalysts on the horizon. We update our investment case on this intriguing small-cap concern in the paragraphs below.

Omeros Corporation (OMER) is a Seattle based commercial-stage biopharmaceutical concern focused on the development of small molecule and protein therapeutics for the treatment of inflammation, complement-mediated diseases, central nervous system disorders, and immune-related diseases, including cancer. The company has one commercial asset, one late-stage candidate being evaluated for three indications, and several early and preclinical compounds. Omeros was formed in 1994 and went public in 2009, raising net proceeds of $61.8 million at $10 a share. The company completed a secondary offering at $13.10 in December 2019 following the release of positive data on its late-stage candidate, OMS721 (narsoplimab). The current market capitalization of OMER is just under $700 million.

Product:

Omidria. Omeros revenue is generated from Omidria, a phenylephrine and ketorolac intraocular solution that is approved for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and reducing postoperative pain. Omidria was launched in 2015 and in 2017 generated net revenue of $64.8 million. However, the Centers for Medicare and Medicaid Services (CMS) determined to let its separate reimbursement under Medicare Part B expire on January 1, 2018, causing sales to plummet ~90%. Fortunately for Omeros, an act of Congress circumvented the CMS and reinstated its pass-through status for two years starting October 1, 2018. Omidria sales rebounded, likely eclipsing $110 million in 2019.

The reason for the pushback from the CMS regarding Omidria has to do with the fact that its active ingredients (phenylephrine and ketorolac) have been around for decades and a similar solution can be prepared by surgeons at a fraction of Omidrias cost. Omeros continues to pursue permanent separate reimbursement for Omidria and the CMS left the door open, indicating a need to find non-opioid alternatives. However, despite the company providing evidence demonstrating Omidria use reduced the need for fentanyl by nearly 80%, the CMS own study suggested otherwise, and it declined to grant Omidria separate payment status. News of this rejection sent shares 16% lower on November 4, 2019.

The CMS continues to analyze and monitor Omidria, and Omeros will exhaust all legislative and administrative avenues to secure permanent or similar status before the September 2020 expiration, including bipartisan anti-opioid legislation that could grant Omidria separate payment status for up to an additional five years. Management remains confident in its ability to gain permanent or similar status beyond September 2020. If it does not prevail, the blow to its top line will be harsh but not likely as severe as in 2018, owing to Omidria receiving its own J-Code in October 2019, which expands separate payment across commercial Med Advantage and Medicaid insurers, as well as in the office setting.

It goes without saying that Omidrias status will alter by a number of years how fast the company will achieve cash-flow positive levels.

Pipeline:

OMS721. In the meantime, Omeros has initiated a rolling BLA for OMS721, its monoclonal antibody (MAB) targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a protein involved in the activation of the complement system, a branch of the bodys immune system that destroys and removes foreign particles and is engaged in the bodys inflammatory response. OMS721 is currently being evaluated in the treatment of three diseases that are all the result of complement system dysfunction.

The indication for which Omeros is filing a BLA is hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a multifactorial disorder induced by systemic vascular endothelial injury that can be triggered by several mechanisms during the transplant process. It occurs in ~40% of the ~60,000 patients undergoing allogenic HSCT in the U.S. and EU annually and is characterized by aggressive blood clotting usually resulting in acute renal failure. Severe cases have a mortality rate north of 90%. There are currently no approved therapies for HSCT-TMA.

That may change as the FDA was impressed enough with February 2018 interim data from OMS721s Phase 2 HSCT-TMA trial, in which median overall survival in 19 patients improved to 347 days versus the historical norm of 21 days (p<0.0001), to treat the small proof-of-concept study as registrational. Omeros released additional data on December 4, 2019, showing OMS721 demonstrated a 68% complete responder rate and a 100-day mortality rate of 19% versus the historical norm of 53% in HSCT-TMA patients who received at least four weeks of dosing. This prompted a 6% rally in shares of OMER, the trading session before the secondary offering was announced.

It should be noted that there are other candidates in the clinic for the HSCT-TMA indication, including Alexions (ALXN) already approved (for other indications) C5 inhibitor Ultomiris. However, Alexion is well behind, planning to initiate a Phase 3 trial (pending FDA feedback) in 1H20. The same can be said regarding Akari Therapeutics (AKTX) nomacopan, which plans to initiate a Phase 3 pediatric study in 1Q20. These schedules should give OMS721 a significant jump on any competition, which should have its BLA completed in 1H20. In addition to Breakthrough Therapy designation from FDA, OMS721 has Orphan drug status in both the U.S. and Europe and will likely receive a priority review from the FDA for HSCT-TMA.

OMS721's second most advanced indication is Immunoglobulin A (IGA) nephropathy, an ailment characterized by inflammation and kidney damage due to a buildup of the IgA antigen that affects 130,000150,000 people in the US and ~200,000 people in Europe with no approved remedies. After positive data from a very small Phase 2 study in which OMS721 reduced proteinuria in IgA nephropathy patients by 50-90%, Omeros finalized the particulars of a Phase 3 trial with the FDA in January 2019. The trials primary endpoint is the same: the relatively novel reduction in proteinuria levels at week 36. By obtaining approval on this endpoint (versus say renal function as measured by estimated glomerular filtration rate), it could potentially shorten the approval process by several years. Enrollment in the ~280-patient study is ongoing and accelerating. For this indication, OMS721 has received Breakthrough Therapy designation from the FDA and Orphan status in both the U.S. and EU.

To date, OMS721 has not been menaced by any significant safety or tolerability issues, which will help it in its pursuit of approval in the treatment of atypical hemolytic uremic syndrome (aHUS), a very rare disorder characterized by uncontrolled activation of the bodys complement system, manifesting itself in strokes, heart attacks, and kidney failures. Approximately 65% of patients diagnosed with aHUS die, require dialysis, or incur permanent renal damage within one year after diagnosis. The only approved treatment on the market is Alexions mAb Soliris, which has a Black Box warning due to risk of fatal infections as a result of suppression of the immune system. In most instances, patients must be immunized with a meningococcal vaccine at least two weeks prior to first administration of Soliris.

Armed with Fast Track and Orphan designations, Omeros only needs to conduct a 40-patient, single-arm (i.e., no control group), open-label Phase 3 trial to satisfy both the FDA and EMA for accelerated and full approvals, respectively. To achieve full approval in the U.S., OMS721 will need to add ~40 patients to the study. The issue confronting Omeros is that the trial began enrollment in 4Q16 and three years later management has not provided any definitive timetable regarding the trials progress, providing a frustrating connotation of accelerated approval for investors.

OMS527. Omeros other clinical asset is OMS527, which is being investigated in patients with addictions and compulsive disorders. After a successful Phase 1 study readout in 3Q19, OMS527 is expected to enter a Phase 2a trial in 2020 with a focus on nicotine addiction.

OMS906 and GPR174. The company also has assets that have demonstrated promise in the pre-clinic. OMS906 is a MASP-3 inhibitor for paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. Pre-clinical research on GPR174 inhibition has displayed promise in immuno-oncology. OMS906 is expected to enter the clinic in 1H20; GPR174 inhibitors will see the clinic when the company has more resources.

On that front, Omeros raised net proceeds of $54.5 million in a December 2019 secondary, which should leave it with ~$70 million at YE19. It has convertible debt with a face value of $210 million ($155 million carrying value) due 2023. The company also has an untapped vehicle through which it can borrow 85% of its receivables up to $50 million. Its cash runway will be contingent on securing separate payment status for Omidria post-September 2020 and the cadence of its development programs.

Like the investment community, Street analysts are somewhat split on Omeros prospects with one outperform rating sandwiched in between two buys and two holds. Their median twelve-month price target, however, is around $25 a share.

There are some unknowns regarding Omeros. Besides Omidrias status, the timing surrounding the completion of two of its pivotal OMS721 trials is still unclear in one instance, after three years. What does seem clear is that the FDA wants to approve OMS721. Given the lack of approved remedies for these complement systems diseases, OMS721 has relatively low hurdles to jump. If eventually approved for all three indications, OMS721 has blockbuster potential. If Omidria obtains five years of separate payment status, it will pave the way for Omeros to finance its own R&D without any more trips to the capital markets. With many shots on goal and what appears to be a helping hand from the FDA, continued investment in the shares of OMER is merited.

Idealism is fine, but as it approaches reality, the costs become prohibitive. William F. Buckley

Bret Jensen is the Founder of and authors articles for the Biotech Forum, Busted IPO Forum, and Insiders Forum

The Biotech Forum sports one of the liveliest collections of seasoned biotech investors on Seeking Alpha along with a 20-stock model portfolio. Join us during every trading day on Live Chat where the community swaps trading ideas, breaking news and opinions around all things Biotech. Initiate your risk-free, two week trial into The Biotech Forum by clicking HERE.

Disclosure: I am/we are long ALXN,OMER. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Continue reading here:
Omeros: 2 Major Catalysts On The Horizon - Seeking Alpha

All events are free. Other topics covered include the impact of new and emerging global infectious diseases such as coronavirus; innovative new methods for detecting ovarian cancer; the promises and pitfalls of gene editing; the rise of antibiotic-resistant superbugs; the worlds second HIV cure; and using stem cells to regenerate damaged tissues.

Using state-of-the-art technology, researchers are now able to grow organoids miniature versions of organs. In Mini-organs in a dish: how organoids are revolutionising research (12 March), Dr Emma Rawlins, The Gurdon Institute, explains how organoids are grown and discusses why this new technology is so important for biomedical research.

Dr Rawlins said: Scientists have been growing animal and human cells in the laboratory for more than 60 years. While these lab-grown cells are a powerful research tool, providing the basis for important developments in modern medicine, including some cancer drugs, anti-HIV therapies and vaccines, they are grown in very artificial conditions and therefore dont resemble any cells in our bodies. Ten years ago, Professor Hans Clevers and colleagues in the Netherlands invented a more complex cell culture system in which mini-organs, or organoids, could be grown. This discovery has led to a worldwide revolution in cell growth.

Scientists in Cambridge are at the forefront of this research, and mini-guts, livers, lungs, kidneys, placentas and even brains are growing in labs all over the city. This ability to study cells in a more natural setting provides many new and interesting research opportunities. Organoid technology has already been used to study human embryonic development, to test personalised treatments for cystic fibrosis and to replace some of the animals used in drug testing. Scientists are now exploring its potential for growing replacement organs, repairing damaged genes and providing personalised treatments for other diseases.

Researchers are also exploring whether they can print biomaterials to repair organs amongst other healthcare benefits. In 3D printing for healthcare (14 March), Dr Yan Yan Shery Huang, Department of Engineering, gives an overview on how 3D printing technologies could transform the way implants are produced, drugs are screened or perhaps even how damaged organs are repaired.

3D printing is already making impacts on patients needing artificial limbs, where the plastic-based prosthesis can be made 'personalised' to shapes and sizes, with relatively low-cost and short production time, Dr Huang said. For 3D printed personalised implants it is more technologically demanding; although, non-biological material-based implants are making their ways to the market and patients, such as 3D printed dental implants and implants for bone structural reconstruction.

Research is now focused on overcoming challenges in using 3D printing for biological materials and even living materials like cells. Applications are focused on two main streams: bioprinting for tissue and organ function replacements, including printing a scaffold for a heart, a human ear, and a blood vessel-permeated-bioreactor; and bioprinting for drug testing pseudo-models of different levels of complexities, from brain to muscles have already been created. Research is continuing, with the aim to reduce and replace animal studies and to improve the predictive power of the models.

Hardening of the arteries is a widespread condition that is a major cause of cardiovascular disease, including heart attacks and stroke. Stroke is also linked to vascular dementia and is one of the nations major causes of adult disability there is a stroke every five minutes in the UK and costs the economy 26b per annum. This figure is expected to triple by 2035. Despite the huge impact that hardened arteries have for human health, there are still no cures. In More than a blocked pipe: the hardening of arteries and their role in stroke and heart attacks (18 March), Dr Nick Evans, Department of Medicine, and Professor Melinda Duer, Department of Chemistry, discuss their combined efforts to find better diagnoses and treatments. They reveal new research and findings on how hardened arteries can be diagnosed more precisely through PET (positron emission tomography), which is proving to be an excellent way to assess carotid calcification in patients and could lead to potential new drug treatment.

Speaking ahead of the event, Professor Duer said: To stop artery calcification, we need to stop the mineral from forming in the artery wall in the first place. We have very recently discovered that a molecule known as poly(ADP ribose), produced by cells in the artery wall that are stressed from fatty deposits around them, is responsible for initiating the formation of the mineral deposits. poly(ADP ribose) gathers calcium and sticks it to the collagen and other molecules in the artery wall, so concentrating the calcium into specific spots in the artery wall which then allows mineral to form. The exciting treatment possibility is to stop stressed cells from making poly(ADP ribose) if it works, it will be the first drug treatment for vascular calcification.

Dr Evans added: Our newly presented research also shows how we can identify the microcalcification in patients using PET and how it gives us an understanding of the different processes causing atherosclerotic plaques (the hardening of arteries) to become damaged and trigger clots to form that cause a stroke.

Scientists and researchers at the forefront of tackling ovarian cancer are also making breakthroughs. In Tackling ovarian cancer: turning the tide on one of the toughest cancers (19 March), Cancer Research UK Cambridge Institute (CRUK CI), the Department of Radiology and AstraZeneca discuss how they are rapidly turning the tide on ovarian cancer using innovative new detection methods and through new treatments, such as Olaparib which was made available in the UK in December 2019.

The new detection methods currently being researched by CRUK CI include liquid biopsy, a process that uses advanced genomic technologies to extract cancer tumour DNA fragments from patients blood plasma. The process offers earlier detection and is far less invasive for patients. Another method is virtual biopsy using state-of-the-art imaging techniques, which is also being researched by the Department of Radiology, University of Cambridge.

The final day of the Festival, Sunday 22nd March, is dedicated to health with over 50 events hosted across Cambridge Biomedical Campus (CBC). Events include Gene editing: rewriting the future! Dr Alasdair Russell, CRUK CI, talks about the CRISPR genome editing revolution, its promise and its pitfalls. In The story of HIV Public Health England and partner organisations discuss the history of HIV in England and show how we have come so far in the diagnosis, treatment and care of people living with the illness. During Open science at the Jeffrey Cheah biomedical centre, visitors can learn more about the new kids on the block on the CBC and chat with scientists about stem cells, infectious diseases, cancer and new therapies. Tours of Royal Papworth Hospital offer a look inside one of the worlds leading heart and lung hospitals and a chance to meet the outstanding teams involved in delivering patient care.

Further related health-related events:

Bookings open on Monday 10 February at 11am.

The full programme can downloaded via Cambridge Science Festival>>>

Image: Talking science with the Department of Materials Science and MetallurgyCredit: Domininkas Zalys

Keep up to date with the Festival on social media via Facebook and Twitter #CamSciFest and Instagram.

This years Festival sponsors and partners are Cambridge University Press, AstraZeneca, Illumina, TTP Group, Anglia Ruskin University, Cambridge Epigenetix, Cambridge Science Centre, Cambridge Junction, IET, Hills Road 6th Form College, British Science Week, Cambridge University Health Partners, Cambridge Academy for Science and Technology, and Walters Kundert Charitable Trust. Media Partners: BBC Radio Cambridgeshire and Cambridge Independent.

View original post here:
Cambridge Science Festival showcases new research at the forefront of healthcare and medicine - Cambridge Network